PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of this work was to determine and compare serum and salivary glucose levels in patients with type II diabetes mellitus (DM).
METHODS: This study had an overall sample size of 100, which consisted of male and female volunteers aged 30-67 years. Both in-depth interviews and physical tests were conducted. Blood and saliva were collected from the participants while fasting, which were analyzed to determine the levels of salivary alpha-amylase (α-amylase). Both the subjects and the controls were instructed to test their blood glucose levels while fasting and it was suggested that HbA1c values will be used for diagnosing diabetes following the guidelines of the American Diabetes Association, Centers for Disease Control, and World Health Organization.
RESULTS: The average age of the control group (Category A) was noted as 47.52±6.28 years, and that of the study group (Category B) was 49.17±7.25 years. In Category A, female (n=23) were 46%, and 54% were male (n=27); and 40% of the people in Category B were female (n=20), and 60% were male (n=30). The majority of patients (54%) in Category B displayed an average level of DM control (n=27), followed by poor control (24%. n=12), well-controlled (20%, n=10), and uncontrolled DM (2%, n=1). Category A had an average salivary α-amylase concentration of 3.1±0.88 U/L, whereas that of Category B was 12.06±2.36 U/L. Thus, the mean salivary α-amylase level of Category B was found to be much higher than that of Category A, and this difference was statistically significant (p<0.001).
CONCLUSIONS: The determination of α-amylase levels in the saliva of individuals suspected of having type II DM has been suggested as a potential diagnostic method. Screenings conducted at healthcare institutions and community health fairs, as well as epidemiological studies, might benefit from this method. We believe that normal clinical practice should include the use of saliva in a broad variety of diagnostic tests.
METHODS: This study had an overall sample size of 100, which consisted of male and female volunteers aged 30-67 years. Both in-depth interviews and physical tests were conducted. Blood and saliva were collected from the participants while fasting, which were analyzed to determine the levels of salivary alpha-amylase (α-amylase). Both the subjects and the controls were instructed to test their blood glucose levels while fasting and it was suggested that HbA1c values will be used for diagnosing diabetes following the guidelines of the American Diabetes Association, Centers for Disease Control, and World Health Organization.
RESULTS: The average age of the control group (Category A) was noted as 47.52±6.28 years, and that of the study group (Category B) was 49.17±7.25 years. In Category A, female (n=23) were 46%, and 54% were male (n=27); and 40% of the people in Category B were female (n=20), and 60% were male (n=30). The majority of patients (54%) in Category B displayed an average level of DM control (n=27), followed by poor control (24%. n=12), well-controlled (20%, n=10), and uncontrolled DM (2%, n=1). Category A had an average salivary α-amylase concentration of 3.1±0.88 U/L, whereas that of Category B was 12.06±2.36 U/L. Thus, the mean salivary α-amylase level of Category B was found to be much higher than that of Category A, and this difference was statistically significant (p<0.001).
CONCLUSIONS: The determination of α-amylase levels in the saliva of individuals suspected of having type II DM has been suggested as a potential diagnostic method. Screenings conducted at healthcare institutions and community health fairs, as well as epidemiological studies, might benefit from this method. We believe that normal clinical practice should include the use of saliva in a broad variety of diagnostic tests.
摘要：
目的：这项工作的目的是确定和比较II型糖尿病（DM）患者的血清和唾液葡萄糖水平。
方法：本研究的总体样本量为100，由30-67岁的男性和女性志愿者组成。进行了深入访谈和身体检查。在禁食期间收集参与者的血液和唾液，对其进行分析以确定唾液α-淀粉酶（α-淀粉酶）的水平。受试者和对照组都被指示在空腹时测试他们的血糖水平，并建议按照美国糖尿病协会的指南，将HbA1c值用于诊断糖尿病。疾病控制中心,和世界卫生组织。
结果：对照组（A类）的平均年龄为47.52±6.28岁，研究组（B类）为49.17±7.25岁。在A类中,女性（n=23）占46％，54%是男性(n=27)；40%的B类人是女性(n=20)，60％为男性（n=30）。B类的大多数患者（54％）显示出DM控制的平均水平（n=27），其次是控制不良（24%。n=12),控制良好(20%，n=10),和不受控制的DM(2%，n=1)。A类的平均唾液α-淀粉酶浓度为3.1±0.88U/L，而B类为12.06±2.36U/L。因此，发现B类的平均唾液α-淀粉酶水平远高于A类，这种差异具有统计学意义（p<0.001）。
结论：已建议确定怀疑患有II型DM的个体的唾液中的α-淀粉酶水平作为一种潜在的诊断方法。在医疗机构和社区卫生展览会上进行的放映，以及流行病学研究，可能会从这种方法中受益。我们认为，正常的临床实践应包括在各种诊断测试中使用唾液。
方法：本研究的总体样本量为100，由30-67岁的男性和女性志愿者组成。进行了深入访谈和身体检查。在禁食期间收集参与者的血液和唾液，对其进行分析以确定唾液α-淀粉酶（α-淀粉酶）的水平。受试者和对照组都被指示在空腹时测试他们的血糖水平，并建议按照美国糖尿病协会的指南，将HbA1c值用于诊断糖尿病。疾病控制中心,和世界卫生组织。
结果：对照组（A类）的平均年龄为47.52±6.28岁，研究组（B类）为49.17±7.25岁。在A类中,女性（n=23）占46％，54%是男性(n=27)；40%的B类人是女性(n=20)，60％为男性（n=30）。B类的大多数患者（54％）显示出DM控制的平均水平（n=27），其次是控制不良（24%。n=12),控制良好(20%，n=10),和不受控制的DM(2%，n=1)。A类的平均唾液α-淀粉酶浓度为3.1±0.88U/L，而B类为12.06±2.36U/L。因此，发现B类的平均唾液α-淀粉酶水平远高于A类，这种差异具有统计学意义（p<0.001）。
结论：已建议确定怀疑患有II型DM的个体的唾液中的α-淀粉酶水平作为一种潜在的诊断方法。在医疗机构和社区卫生展览会上进行的放映，以及流行病学研究，可能会从这种方法中受益。我们认为，正常的临床实践应包括在各种诊断测试中使用唾液。
